Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study

(Frontiers in Pharmacology)

doi: 10.3389/fphar.2024.1443175